Sugi Predict

Sugi Predict / Compounds / SCHEMBL5019074

SCHEMBL5019074

SCHEMBL5019074

O=C(NCCNCCNC(=O)OCc1ccccc1)OCc1ccccc1

nearest known ligand 0.79

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 1/20 0.73
▸ SMN1; SMN2 Q16637 1/20 0.73
▸ HTT P42858 1/20 0.69
▸ TGM2 P21980 1/20 0.60
▸ L3MBTL1 Q9Y468 2/20 0.58
▸ KEAP1 Q14145 2/20 0.58
▸ NFE2L2 Q16236 2/20 0.58
▸ MAPT P10636 1/20 0.57
▸ SLC1A3 P43003 1/20 0.56
▸ SLC1A1 P43005 1/20 0.56
▸ MEN1 O00255 1/20 0.55
▸ KMT2A Q03164 1/20 0.55
▸ CA12 O43570 1/20 0.53
▸ CA1 P00915 1/20 0.53
▸ CA2 P00918 1/20 0.53
▸ CA9 Q16790 1/20 0.53
▸ KAT2B Q92831 1/20 0.52
▸ GAA P10253 1/20 0.52
▸ IDO1 P14902 1/20 0.52
▸ TDO2 P48775 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL4506331 0.98 LMNA (0.71) LMNASMN1; SMN2HTTTGM2L3MBTL1
SCHEMBL13055383 0.94 LMNA (0.80) LMNASMN1; SMN2HTTTGM2L3MBTL1
SCHEMBL14486856 0.92 HTT (0.64) LMNASMN1; SMN2HTTTGM2L3MBTL1
SCHEMBL14985738 0.92 LMNA (0.63) LMNASMN1; SMN2HTTTGM2L3MBTL1
SCHEMBL15671941 0.92 HTT (0.64) LMNASMN1; SMN2HTTTGM2L3MBTL1
SCHEMBL21338348 0.92 LMNA (0.63) LMNASMN1; SMN2HTTTGM2L3MBTL1
SCHEMBL13365569 0.92 LMNA (0.67) LMNASMN1; SMN2HTTTGM2L3MBTL1
SCHEMBL11376465 0.90 HTT (0.70) LMNASMN1; SMN2HTTTGM2L3MBTL1
SCHEMBL7364819 0.90 LMNA (0.65) LMNASMN1; SMN2HTTTGM2L3MBTL1
SCHEMBL2402780 0.90 HTT (0.74) LMNASMN1; SMN2HTTTGM2L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4572795-A2 METHODS AND COMPOSITIONS FOR TREATING CANCER WITH CANCER-BINDING ADJUVANTS The University of Chicago (US) 2025-06-25 — — EP disclosed
WO-2024241157-A1 COMPOSITIONS FOR PROLONGING THE SHELF LIFE OF A FOOD PRODUCT, PROCESS FOR PRODUCING THE COMPOSITIONS, USES THEREOF Agree NET S.r.l. (IT) 2024-11-28 — — WO disclosed
EP-4464162-A1 COMPOSITIONS FOR EXTENDING THE SHELF LIFE OF A FOOD PRODUCT, METHOD FOR PRODUCING THE COMPOSITIONS, USES THEREOF Agree NET S.r.l. (IT) 2024-11-20 — — EP disclosed
WO-2024040169-A2 METHODS AND COMPOSITIONS FOR TREATING CANCER WITH CANCER-BINDING ADJUVANTS THE UNIVERSITY OF CHICAGO (US) 2024-02-22 — — WO disclosed
EP-3976061-A1 METHODS AND COMPOSITIONS FOR TREATING CANCER WITH CANCER-TARGETED ADJUVANTS The University of Chicago (US) 2022-04-06 — — EP disclosed
US-11241503-B2 Oxadiazole linkers and use thereof NEWBIO THERAPEUTICS, INC. (CN) 2022-02-08 — — US disclosed
US-20210154320-A1 OXADIAZOLE LINKERS AND USE THEREOF NEWBIO THERAPEUTICS, INC. (CN) 2021-05-27 — — US disclosed
US-10836706-B2 Bacterial efflux pump inhibitors RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2020-11-17 — — US disclosed
EP-2920157-B1 DI-MACROCYCLES LUMIPHORE INC (US) 2019-09-11 — — EP disclosed
US-20190055188-A1 BACTERIAL EFFLUX PUMP INHIBITORS RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY 2019-02-21 — — US disclosed
EP-0836485-A2 CASCADE POLYMER COMPLEXES SCHERING AKTIENGESELLSCHAFT (DE) 1998-04-22 — — EP disclosed
EP-0832150-A1 CASCADE POLYMERS WITH IODINE-CONTAINING AROMATIC COMPOUNDS SCHERING AKTIENGESELLSCHAFT (DE) 1998-04-01 — — EP disclosed
WO-1998001163-A2 PSEUDOPOLYROTAXANES SCHERING AKTIENGESELLSCHAFT (DE) 1998-01-15 — — WO disclosed
US-5676923-A SOLUBLE, STABLE, ORGAN-SPECIFIC NUCLEAR MAGNETIC RESONANCE CONTRAST AGENT SCHERING AKTIENGESELLSCHAFT (DE) 1997-10-14 — — US disclosed
WO-1997023245-A1 CASCADE POLYMER COMPLEXES, PROCESS FOR PRODUCING THE SAME AND PHARMACEUTICALS CONTAINING THE SAME SCHERING AKTIENGESELLSCHAFT (DE) 1997-07-03 — — WO disclosed
EP-0768898-A1 CASCADE-POLYMER COMPLEXES AND METHODS OF PRODUCING THE SAME SCHERING AKTIENGESELLSCHAFT (DE) 1997-04-23 — — EP disclosed
WO-1997002051-A2 CASCADE POLYMER COMPLEXES SCHERING AKTIENGESELLSCHAFT (DE) 1997-01-23 — — WO disclosed
WO-1996041830-A1 CASCADE POLYMERS WITH IODINE-CONTAINING AROMATIC COMPOUNDS SCHERING AKTIENGESELLSCHAFT (DE) 1996-12-27 — — WO disclosed
US-5514810-A Process for the production of DTPA-tetraesters of terminal carboxylic acids SCHERING AKTIENGESELLSCHAFT (DE) 1996-05-07 — — US disclosed
WO-1996001655-A1 CASCADE-POLYMER COMPLEXES AND METHODS OF PRODUCING THE SAME SCHERING AKTIENGESELLSCHAFT (DE) 1996-01-25 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10836706-B2 Bacterial efflux pump inhibitors ABCB11, ABCB1, SLC47A1 LMNA 3655/4885SMN1; SMN2 4878/4885HTT 4490/4885
US-20190055188-A1 BACTERIAL EFFLUX PUMP INHIBITORS ABCB11, ABCB1, SLC47A1 LMNA 3655/4885SMN1; SMN2 4878/4885HTT 4490/4885
US-11241503-B2 Oxadiazole linkers and use thereof OXA1L, CD99, IGLV6-57 LMNA 3946/4885SMN1; SMN2 730/4885HTT 2893/4885
US-20210154320-A1 OXADIAZOLE LINKERS AND USE THEREOF OXA1L, CD99, IGLV6-57 LMNA 3946/4885SMN1; SMN2 730/4885HTT 2893/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.